Peptide YY (3-36)
Also known as: AC162352, Peptide YY (3-36), Peptide YY fragment 3-36, PYY 3-36, PYY(3-36), PYY3-36
Source Peptide YY (3-36) at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Peptide YY (3-36) is a 34‑amino‑acid fragment of the endogenous peptide YY hormone. It acts centrally via Y2 receptors to suppress food intake and peripherally to delay gastric emptying, and is being studied for obesity and metabolic disease.
Mechanism of Action
Selective agonist of Y2 (and Y5) receptors; reduces appetite and slows gastric emptying
Routes of Administration
Goals & Uses
- Post-bariatric surgery gut hormone modulationMetabolic / SurgicalLow
- Type 2 diabetes / glycemic controlMetabolic / EndocrineLow
- Appetite suppression / Reduction of food intakeMetabolic / ObesityModerate
- Appetite suppressionMetabolicModerate
- Obesity treatmentMetabolicModerate
- Weight loss in obesityMetabolic / ObesityModerate
Contraindications
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Severe gastrointestinal dysmotilityGastrointestinalModerate
- severe gastrointestinal obstructionGastrointestinalHigh
- Eating disorders (anorexia nervosa)Psychiatric / NutritionalHigh
Adverse Effects
- Abdominal discomfortGastrointestinalCommon
- Injection site reactionsLocalUncommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- Dizziness / lightheadednessNeurologicUncommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalUncommonForceful expulsion of stomach contents
- Nasal irritation / epistaxisLocal / NasalUncommon
Drug Interactions
- Other Y‑receptor agonistsHigh
- Oxyntomodulin / GLP-1/glucagon dual agonistsLow
- GLP‑1 receptor agonistsModerate
- GLP-1 receptor agonists (e.g., liraglutide, semaglutide)Moderate
- Opioid analgesicsModerate
Population Constraints
- Pediatric patientsAgeRelative
- Breastfeeding womenReproductiveRelative
- Children (<12 y)PediatricRelative
- Elderly (>75 y)AgeRelative
- Patients with renal impairmentOrgan ImpairmentRelative
- Elderly patientsAgeRelative
Regulatory Status
- European UnionInvestigationalClinical research use only.
- United StatesInvestigationalPhase 2 trials for obesity.
- United KingdomInvestigationalNot licensed.
Not approved for any indication; used only in clinical trials and experimental settings.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Peptide YY (3-36)?
Peptide YY (3-36) is a 34‑amino‑acid fragment of the endogenous peptide YY hormone. It acts centrally via Y2 receptors to suppress food intake and peripherally to delay gastric emptying, and is being studied for obesity and metabolic disease.
What is Peptide YY (3-36) used for?
Peptide YY (3-36) is educationally associated with: Post-bariatric surgery gut hormone modulation, Type 2 diabetes / glycemic control, Appetite suppression / Reduction of food intake, Appetite suppression, Obesity treatment, Weight loss in obesity. Educational only — not medical advice.
How is Peptide YY (3-36) administered?
Recorded routes of administration: Intravenous, Nasal, Oral, Subcutaneous.
What are the potential side effects of Peptide YY (3-36)?
Reported adverse effects include: Abdominal discomfort, Injection site reactions, Headache, Dizziness / lightheadedness, Nausea, Vomiting, Nasal irritation / epistaxis. This list is not exhaustive — consult a qualified clinician.
Who should avoid Peptide YY (3-36)?
Recorded contraindications: Pregnancy, Severe gastrointestinal dysmotility, severe gastrointestinal obstruction, Eating disorders (anorexia nervosa). Consult a qualified clinician before use.